Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0305 Monotherapy and Combinations in Multiple Myeloma
NCT06106945Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2023
- Primary completion
- Jan 2028
- Countries
- 10
01
Overview
A Phase 2 trial of AZD0305 in multiple myeloma (MM), sponsored by AstraZeneca. Started Dec 2023; status: recruiting.
02
Drugs
AZD0305
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06106945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06106945.